Efficacy and safety of crizotinib in patients (pts) with advanced <i>MET</i> exon 14-altered non-small cell lung cancer (NSCLC).
Alexander Drilon(Memorial Sloan Kettering Cancer Center), Paul K. Paik(Memorial Sloan Kettering Cancer Center), Jared Weiss(University of North Carolina at Chapel Hill), Maria Winter(Pfizer (United States)), Gregory J. Riely(Memorial Sloan Kettering Cancer Center), Keith D. Wilner(Pfizer (United States)), Katherine Monti(Rho (United States)), Mark A. Socinski(Florida Hospital Cancer Institute), D. Ross Camidge(University of Colorado Denver), Sai‐Hong Ignatius Ou(University of California, Irvine Medical Center), Jeffrey W. Clark(Massachusetts General Hospital), Sherry Wang(Pfizer (United States))
Cited by 113
Related Papers
International Association for the Study of Lung Cancer/American Thoracic Society/European Respiratory Society International Multidisciplinary Classification of Lung Adenocarcinoma
|Journal of Thoracic Oncology|2011|4.8k
Anaplastic Lymphoma Kinase Inhibition in Non–Small-Cell Lung Cancer
|New England Journal of Medicine|2010|4.5k
Tumor mutational load predicts survival after immunotherapy across multiple cancer types
|Nature Genetics|2019|4.4k
Crizotinib versus Chemotherapy in Advanced <i>ALK</i> -Positive Lung Cancer
|New England Journal of Medicine|2013|3.4k
First-Line Crizotinib versus Chemotherapy in <i>ALK</i>-Positive Lung Cancer
|New England Journal of Medicine|2014|3.2k